SMSPHARMA vs THEMISMED: Stock Comparison
SMS PHARMACEUTICALS is the larger company by market capitalisation. SMS PHARMACEUTICALS shows a higher ROE, a higher ROCE and a higher net margin, while THEMIS MEDICARE shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SMSPHARMA leads 5; THEMISMED leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| Live Price | ₹518.3 | ₹98.72 |
| Day Change | 6.69% | 1.23% |
| Volume | 26.33 L | 15,352 |
| 52-Week High | ₹494.45 | ₹140.6 |
| 52-Week Low | ₹270.1 | ₹64.95 |
| Distance from 52W High | 4.82% | -29.79% |
Valuation
| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| Market Cap | ₹4,892 Cr | ₹910 Cr |
| P/E Ratio | 44.45x | 22.24x |
| P/B Ratio | 5.81x | 2.23x |
| EPS | ₹2.23 | ₹2.67 |
| Book Value | ₹83.91 | ₹43.28 |
| Dividend Yield | 0.16% | 0.52% |
Growth
| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| Revenue Growth (TTM YoY) | -4.1% | 6.7% |
| EPS Growth (TTM YoY) | 49.2% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| ROE | 10.89% | 0.29% |
| ROCE | 9.59% | -0.27% |
| Net Margin | 11.5% | 0.33% |
| Operating Margin | 15.71% | -0.42% |
| Debt to Equity | 0.45x | 0.25x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SMSPHARMA | THEMISMED |
|---|---|---|
| Promoter Holding | 68.07% | 57.5% |
| FII Holding | 1.18%▲ 0.53 pp | 0.01% |
| DII Holding | 0.2%▼ 2.63 pp | 0.01% |
| Public Holding | 30.56%▲ 2.11 pp | 32.87% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SMS PHARMACEUTICALS and THEMIS MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.